Information Provided By:
Fly News Breaks for August 5, 2019
BIOS
Aug 5, 2019 | 08:45 EDT
Lake Street analyst Brooks O'Neil says he learned recently from talking with Option Care CFO Mike Shapiro that Option Care will be deemed the acquirer of BioScrip. The analyst previously thought BioScrip would be the acquirer, and he views this new development as a positive for the shares. BioScrip being added on top of historical Option Care will accelerate revenue growth and margins will go up, O'Neil tells investors in a research note. "Those two things are likely to be well received by investors," says the analyst, who expects this trend for "at least" the first five-to-six quarters post the combination. He affirms a Buy rating on BioScrip with a $4.50 price target.
News For BIOS From the Last 2 Days
There are no results for your query BIOS